Fig. 5

Evaluation of the neutralization capacity of mAbs against EMCVs in vivo. Note: A. Monitoring of body weight in different groups for a period of 14 days. B. Survival rate of the mice in each group after challenge with EMCV for a period of 14 days; C. Viral load in different tissues of the mice, including the heart, liver, spleen, lung, kidney, and brain. The samples were collected over a period of 4 days, and a p value of < 0.05 was considered to indicate statistical significance. As shown in each panel of Fig. 4, Group A received treatment 24 h prior to infection, Group B received treatment 24 h after infection, and Group C underwent treatment at intervals of 1, 24, 48 and 72 h post infection. Group D was challenged with only EMCV, whereas Group E received treatment at 24 and 48 h post infection. Group F served as the control and received only PBS without viral challenge